PHARMACY

Depomed sells royalty, milestone interests in Type 2 diabetes drugs for $240.5 million

BY Alaric DeArment

NEWARK, Calif. — Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

The drug maker announced that it had sold its interest in the Type 2 diabetes therapeutic area to PDL for $240.5 million, which it plans to use to acquire rights to products it said would drive long-term growth and build on its expertise in pain and neurology.

The interests include payments accruing from and after Oct. 1 from Santarus, for Glumetza (metformin hydrochloride extended-release tablets) in the United States; from Merck for Janumet XR (sitagliptin and metformin hydrochloride extended-release); from Johnson & Johnson for potential future milestones and sales of Invokana (canagliflozin) and extended-release metformin; from Boehringer Ingelheim for potential future milestones and sales of experimental drugs; and from LG and Valeant for sales of extended-release metformin in Korea and Canada, respectively.

"Through this sale of our Type 2 diabetes milestone and royalty payments, we have generated a significant infusion of cash equal to approximately 55% of our market capitalization without issuing any equity or incurring any debt," Depomed president and CEO Jim Schoeneck said. "We intend to focus our cash balance of over $300 million to fund future product acquisitions capable of driving growth into the next decade."

Schoeneck said he expected such current Depomed products as the restless legs syndrome drug Gralise (gabapentin), the pain drug Lazanda (fentanyl nasal spray) and the actinic keratosis drug Zipsor (diclofenac potassium) to drive sales growth, and the company has retained its royalty and milestone interests in other collaborations, including agreements with Mallinckrodt, Ironwood and Johnson & Johnson.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

NASP elects Walgreens’ Mike Ellis as first president

BY Alaric DeArment

ALEXANDRIA, Va. — The National Association of Specialty Pharmacy has named Walgreens corporate VP specialty pharmacy and infusion services as its first president, the organization said Tuesday.

Ellis previously worked as SVP specialty trade relations and contracting and pharmaceutical services for CVS Caremark, before joining Walgreens in 2011. He has more than 32 years’ experience in specialty pharmacy and infusion and also has worked at AdvancePCS, Olsten Health Services and Quantum Health Resources. Walgreens joined NASP as a founding member last year, and Ellis was elected at the NASP board of directors’ Oct. 14 meeting; he will serve a one-year term through October 2014.

"This is an exciting time for specialty pharmacy, and I’m excited to work with my colleagues on this distinguished board of directors to advance NASP’s mission and create a stronger, more unified voice for all stakeholders," Ellis said. "At Walgreens, we share eNASP’s dedication to serve the needs of patients living with complex, chronic health conditions and support the pharmacists they work with on a daily basis."

Walgreens uses an integrated, multichannel model for its specialty and infusion business, focusing on creating an optimal patient experience that supports improved health outcomes, NASP said, while also offering pipeline insights, custom reporting and clinical and utilization management programs to help payers manage costs.

"We are honored to work with Mike as our first president, guiding NASP forward as it continues to lead the specialty pharmacy industry," NASP CEO Gary Cohen said. "Walgreens is a strong supporter of our membership and industry as a whole, and we believe Mike will provide both the vision and leadership necessary to steer NASP and the specialty pharmacy industry to the next level."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Fairview Pharmacy Services adopts Mscripts mobile health platform

BY Alaric DeArment

MINNEAPOLIS — A pharmacy chain based in Minnesota is offering a new mobile app and web portal for its retail customers under a partnership with San Francisco-based Mscripts, the chain said Tuesday.

Fairview Pharmacy Services, which runs about 30 retail pharmacies across the state and also specialty, compounding and mail-order facilities, said the new app would allow customers to scan and refill prescriptions, receive pickup and dosage reminders and locate stores and specials. Non-smartphone users will have a text-messaging option.

"Fairview Pharmacy prides itself on our neighborhood focus and medical expertise," Fairview chief information officer Marlaine Villas said. "We are committed to delivering the finest, most innovative health solutions to our customers. Our mobile pharmacy solution furthers this mission, while affording our customers the ease and convenience of using their mobile phones to manage their prescription needs and access other services across our pharmacy — whether they be in the neighborhood or across the country."

The mobile app will operate on a secure network and is integrated with McKesson’s EnterpriseRx pharmacy-management system, allowing Fairview to offer a variety of mobile communication pathways. The app will be available starting later this year, free of charge, for iPhone and Android users.

"Fairview Pharmacy is strengthening its ties to the community by expanding the mobile adherence services it provides to its patients," Mscripts CEO Mark Cullen said. "The mobile phone has become a trusted, integral part of daily lives, and Fairview is making it easier for customers to refill prescriptions and manage their health information wherever they may be."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?